Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier.
Gene and cell therapies have the potential to prevent, halt, or reverse diseases of the retina in patients with currently incurable blinding conditions. Over the past 2 decades, major advances in our understanding of the pathobiologic basis of retinal diseases, coupled with growth of gene transfer and cell transplantation biotechnologies, have created optimism that previously blinding retinal conditions may be treatable. It is now possible to deliver cloned genes safely and stably to specific retinal cell types in humans. Preliminary results testing gene augmentation strategies in human recessive diseases suggest promising safety and efficacy profiles, including improved visual function outcomes over extended periods. Additional gene-based strategies under development include approaches to autosomal dominant disease ("gain of function"), attempts to deliver genes encoding therapeutic proteins with proven mechanisms of action interfering with specific disease pathways, and approaches that could be used to render retinal cells other than atrophied photoreceptors light sensitive. In the programs that are the furthest along-pivotal regulatory safety and efficacy trials studying individuals with retinal degeneration resulting from RPE65 mutations-initial results reveal a robust safety profile and clinically significant improvements in visual function, thereby making this program a frontrunner for the first approved gene therapy product in the United States. Similar to gene therapy, progress in regenerative or stem cell-based transplantation strategies has been substantial. It is now possible to deliver safely stem cell-derived, terminally differentiated, biologically and genetically defined retinal pigment epithelium (RPE) to the diseased human eye. Although demonstration of clinical efficacy is still well behind the gene therapy field, multiple programs investigating regenerative strategies in RPE disease are beginning to enroll subjects, and initial results suggest possible signs of efficacy. Stem cells capable of becoming other retinal cell types, such as photoreceptors, are on the cusp of clinical trials. Stem cell-derived transplants can be delivered to precise target locations in the eye, and their ability to ameliorate, reverse, regenerate, or neuroprotect against disease processes can be assessed. Results from these studies will provide foundational knowledge that may lead to clinically significant therapies for currently untreatable retinal disease.
Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford and Oxford University Eye Hospital, NHS Foundation Trust, NIHR Biomedical Research Centre, Oxford, United Kingdom; Moorfields Eye Hospital, NHS Foundation Trust, NIHR Biomedical Research Centre, London, United Kingdom. Electronic address: enquiries@eye.ox.ac.uk.
Robert E
RE
MacLaren
Center for Advanced Retinal and Ocular Therapeutics, Department of Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Jean
J
Bennett
Retina Division, Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Steven D
SD
Schwartz
D000229:Dependovirus / Q000235:genetics; D053595:Embryonic Stem Cells / Q000166:cytology; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D039904:Pluripotent Stem Cells / Q000166:cytology; D044968:Regenerative Medicine; D012164:Retinal Diseases / Q000628:therapy*; D055213:Retinal Pigment Epithelium / Q000637:transplantation; D033581:Stem Cell Transplantation / Q000379:methods*; D014181:Transplantation Immunology
Nature. 2014 Sep 18;513(7518):287-8
25230622
Mol Ther. 2009 Apr;17(4):593-9
19174761
Hum Genet. 2016 Mar;135(3):327-43
26825853
Curr Gene Ther. 2013 Apr;13(2):139-51
23320477
Lancet. 2014 Mar 29;383(9923):1129-37
24439297
Sci Transl Med. 2013 Jun 12;5(189):189ra76
23761039
N Engl J Med. 2016 May 19;374(20):1996-8
27120491
Cold Spring Harb Perspect Med. 2014 Oct 16;5(2):a017111
25324231
Lancet. 2009 Nov 7;374(9701):1597-605
19854499
Hum Mol Genet. 2014 Jun 1;23(11):2926-39
24419317
Lancet. 2015 Dec 12;386(10011):2395-403
26431823
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3896-901
16505355
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4151-60
15505069
Invest Ophthalmol Vis Sci. 2013 Jun 12;54(6):4061-71
23620430
Mol Vis. 2006 Apr 18;12:384-8
16636657
Exp Eye Res. 2002 Jun;74(6):719-35
12126945
Am J Ophthalmol. 2008 Aug;146(2):172-182
18547537
Gene Ther. 2012 Feb;19(2):145-53
22052240
Lancet. 2015 Feb 7;385(9967):509-16
25458728
N Engl J Med. 2015 May 14;372(20):1920-6
25936984
Nat Biotechnol. 2016 Apr;34(4):424-9
26950749
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):E517-25
23341635
PLoS One. 2012;7(8):e43251
22927954
Hum Gene Ther. 2012 Oct;23(10):1101-15
22845794
Hum Mol Genet. 2014 Sep 15;23(R1):R9-R16
24647603
Cell. 2015 May 7;161(4):817-32
25957687
Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3167-74
1748547
J Control Release. 2015 Dec 10;219:471-87
26439665
Mol Ther. 2001 Nov;4(5):461-72
11708883
Gene Ther. 2010 Sep;17(9):1162-74
20428215
Prog Retin Eye Res. 2014 Nov;43:108-28
25124745
Exp Neurol. 1999 Sep;159(1):21-33
10486172
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1101-6
23288902
Mol Ther. 2015 Aug;23(8):1308-19
25896245
Ophthalmology. 2007 Mar;114(3):561-70
17324698
Cell. 2007 Nov 30;131(5):861-72
18035408
Arch Ophthalmol. 2012 Jan;130(1):9-24
21911650
Am J Ophthalmol. 2012 Jan;153(1):120-7.e2
21907969
Gene Ther. 2012 Feb;19(2):169-75
21993174
Hum Gene Ther Clin Dev. 2015 Dec;26(4):208-10
26684444
Lancet. 2016 Aug 13;388(10045):661-72
27375040
Science. 2016 Jan 22;351(6271):407-411
26721686